Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 82 entries
View as:

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Phase: N/A Priority: Normal
NCT ID: NCT00963001 Org: User:
Start: 09/30/09 End: 11/30/09 Due: 11/30/10

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT01104870 Org: User:
Start: 04/30/10 End: 01/31/13 Due: 01/31/14

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

Phase: N/A Priority: Normal
NCT ID: NCT03950739 Org: User:
Start: 09/17/19 End: 08/22/23 Due: 08/22/24

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02149095 Org: User:
Start: 07/31/14 End: - Due: -

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02279745 Org: User:
Start: 07/08/15 End: 03/29/21 Due: 03/29/22

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT00325442 Org: User:
Start: 10/31/06 End: 12/31/10 Due: 12/31/11

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT01028651 Org: User:
Start: 01/31/11 End: 04/30/13 Due: 04/30/14

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

Phase: N/A Priority: Normal
NCT ID: NCT01153386 Org: User:
Start: 07/31/10 End: 08/31/10 Due: 08/31/11

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH

Phase: N/A Priority: Normal
NCT ID: NCT01557647 Org: User:
Start: 06/30/12 End: 06/30/16 Due: 06/30/17

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Phase: N/A Priority: Normal
NCT ID: NCT03043651 Org: User:
Start: 01/30/18 End: 03/02/20 Due: 03/02/21

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

Phase: N/A Priority: Normal
NCT ID: NCT00060996 Org: User:
Start: 02/28/03 End: 09/30/04 Due: 09/30/05

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00887978 Org: User:
Start: 06/30/09 End: 07/31/11 Due: 07/31/12

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients with ESRD

Phase: N/A Priority: Normal
NCT ID: NCT06878560 Org: User:
Start: 06/30/25 End: 06/01/28 Due: 06/01/29

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Phase: N/A Priority: Normal
NCT ID: NCT00643604 Org: User:
Start: 03/31/08 End: 02/29/12 Due: 02/28/13

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT00325403 Org: User:
Start: 10/31/06 End: 04/30/11 Due: 04/30/12

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02318758 Org: User:
Start: 09/30/14 End: 12/31/14 Due: 12/31/15

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Phase: N/A Priority: Normal
NCT ID: NCT02261883 Org: User:
Start: 07/29/15 End: 05/17/23 Due: 05/17/24

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01560624 Org: User:
Start: 06/26/12 End: 06/24/18 Due: 06/24/19

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Phase: N/A Priority: Normal
NCT ID: NCT03683186 Org: User:
Start: 09/23/19 End: 12/31/26 Due: 12/31/27

Inhaled Treprostinil for PAH: Open-label Extension

Phase: N/A Priority: Normal
NCT ID: NCT01557660 Org: User:
Start: 06/30/12 End: 12/31/18 Due: 12/31/19

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

Phase: N/A Priority: Normal
NCT ID: NCT01131845 Org: User:
Start: 05/31/10 End: 09/30/10 Due: 09/30/11

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02279160 Org: User:
Start: 12/31/14 End: 06/30/17 Due: 06/30/18

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT00147199 Org: User:
Start: 06/30/05 End: 10/31/07 Due: 10/31/08

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Phase: N/A Priority: Normal
NCT ID: NCT03055234 Org: User:
Start: 06/30/17 End: 12/31/22 Due: 12/31/23

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Phase: N/A Priority: Normal
NCT ID: NCT06388421 Org: User:
Start: 01/23/25 End: 11/30/30 Due: 11/30/31